US 11338013
Combination therapy for C3 inhibition
granted A61KA61K31/713A61K38/12
Quick answer
US patent 11338013 (Combination therapy for C3 inhibition) held by Apellis Pharmaceuticals, Inc. expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Apellis Pharmaceuticals, Inc.
- Grant date
- Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/713, A61K38/12, A61K45/06, A61K47/60